期刊文献+

不稳定性心绞痛患者血管紧张素基因多态性与GLP-1的相关性研究

Relevant Research on Unstable Angina Angiotensin Gene Polymorphism Patients and GLP-1
下载PDF
导出
摘要 目的:观察不稳定性心绞痛患者的血管紧张素转换酶基因插入/缺失多态性与胰高血糖素样肽1(glucagon-like peptide-1,GLP-1)的相关性,从而有效的指导中医的辨证施治。方法:应用聚合酶链反应(polymerase chain reaction,PCR)技术检测60例不稳定性心绞痛患者(观察组)和60例健康者(对照组)的血管紧张素基因插入(insertion,I)与缺失(deletion,D)多态性;采用双抗体一步夹心法酶联免疫吸附试验(double antibody-step sandwich enzyme-linked immunosorbent assay,ELISA)对胰高血糖素样肽1受体(glucagon-like peptide-1 receptor,GLP-1R)进行检测。结果:观察组血管紧张素DD基因型和血管紧张素D等位基因频率均高于对照组。GLP-1与不稳定性心绞痛血管紧张素DD基因型频率存在一定的联系。结论:DD基因型和D等位基因频率与不稳定性心绞痛的发生率呈正相关;不稳定性心绞痛血管紧张素DD基因型与GLP-1水平存在负相关性。 Objective:To observe patients with unstable angina angiotensin converting enzyme gene insertion / deletion polymorphism and glucagon-like peptide 1(GLP-1)correlation. Thus more effective guidance dialectical therapy of traditional Chinese medicine. Methods:Polymerase chain reaction( PCR)technology to detect 60 cases of patients with unstable angina( observation group)and 60 healthy sub- jects( control group)of angiotensin( ACE)gene insertion( I)abulnd deletion( D)and more normality;Adopted by double antibody-step sandwich enzyme-linked immunosorbent assay(ELISA)for glucagon-like peptide-1 receptor(GLP1R)were detected. Results:Unstable angina group compared with the control group,DD genotype and D allele frequencies were higher. Glucagon-like peptide 1has some links with unstable angina ACE-DD genotype frequencies. Conclusion:DD genotype and D allele frequency are positively correlated with un- stable angina,and there is a negative correlation between unstable angina ACE-DD genotype and glucagon-like peptide-1.
出处 《中医学报》 CAS 2015年第2期270-272,共3页 Acta Chinese Medicine
基金 河南省科技攻关课题(122102310079)
关键词 基因多态性 不稳定性心绞痛 胰高血糖素样肽1 gene polymorphism unstable angina glucagon-like peptide-1
  • 相关文献

参考文献10

  • 1Clarke SJ, McCmaick LM, Dutka DP. Optimising cardioprotection during myocardial ischaemia:targeting potential intracellular pathways with glucagon-like peptide-1 [ J]. Cardiovasc Diabeto1,2014,13 ( 1 ) : 12.
  • 2班绎娟,许樟荣.胰高血糖素样肽-1类似物治疗2型糖尿病的研究进展[J].中华老年多器官疾病杂志,2014,13(5):391-395. 被引量:9
  • 3Johnston CI. Tissue angiotensin converting enzyme in cardiac and vas- cular hypertrophy, repair, and remodeling [ J ]. Hypertension, 1994,23 (2) :258 -268.
  • 4高慧锋.益气化痰法治疗不稳定性心绞痛临床研究[J].中医学报,2012,27(11):1481-1482. 被引量:9
  • 5l"amaki S, Iwai N, Tsujita Y, et al. Genetic polymorphism of CYP11 B2 gene and hypertension in Japanese[ J ]. Hypertension, 1999,33 (1 pt2) : 266 - 270.
  • 6Dzau V. The cardiovascular continuum and renin-angiotensin-aldoste- rone system blockade [ J ]. J Hypertens Suppl, 2005,23 ( 1 ) : $9 - S17.
  • 7Katsuya T, Koike G, Yee TW, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease[ J]. Lancet, 1995,345 ( 8965 ) : 1600 - 1603.
  • 8Buraczynska M, Pijanowski Z, Spasiewicz D, et al. Renin-angiotensin system gene polymorphisms : assessment of the risk of coronary heart disease [ J ]. Kardiol Po1,2003,58 ( 1 ) : 1 - 9.
  • 9钟伟,邢庆盛,刘志刚,魏岳斌.益气活血方治疗冠心病心绞痛临床研究[J].中医学报,2014,29(3):402-403. 被引量:14
  • 10杨健,胡运军.胸痹病因病机探析[J].河南中医,2013,33(7):1062-1063. 被引量:16

二级参考文献42

  • 1张秋雁,邓冰湘.冠心病心绞痛临床中医证型分布的回顾性分析[J].中医研究,2005,18(11):23-24. 被引量:108
  • 2范秉均.温中补虚法为主治疗虚寒性胸痹心痛的临床研究[J].中医药学刊,2006,24(2):352-354. 被引量:4
  • 3国家中医药管理局.中医病症诊断疗效标准[S].南京:南京中医药大学出版社,1994..
  • 4颜红兵,张生,霍勇,等.2007年中国专家共识———不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[M].北京:中国环境出版社,2007:20-25.
  • 5国际心脏学会和协会及世界卫生组织命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(11):75.
  • 6廖伯寿.他汀类药物与血管内皮功能的改善[J].医护论坛,2009,16(10):156.
  • 7Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-958.
  • 8Deaton CF. What do we know about the secretion and degradation of incretin hormones[J]? Regul Pept, 2005, 128(2): 117-124.
  • 9Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes[J]. Diabetes Care, 2013, 36(10): 3276-3282.
  • 10Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU)[J]. Diabet Med, 2009, 26(3): 268-278.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部